Population Dynamics and Human Strategies in Northwestern Patagonia

In this paper we evaluate the role of human strategies in the Andean Piedmont from northern Patagonia across the Holocene. Specifically, we present the analysis of the Early Holocene-Late Holocene archaeological record of Salamanca cave (Mendoza-Argentina). We identified technological changes that occurred during the Late Holocene and the implications of a human occupation hiatus in the Middle Holocene. We follow a multiproxy approach by the analysis of radiocarbon dates, archaeofaunal remains, ceramic, lithics and XRF obsidian sourcing. We also discuss a detailed stratigraphic sequence by geomorphological descriptions, the construction of a radiocarbon sequence model and summed probability distributions, compared with other archaeological sites in the region. We conclude that after the Middle Holocene archaeological hiatus, human populations grew while guanaco populations dropped. The imbalance between demography and resources boosted the incorporation of new technologies such as ceramics and the bow and arrow, allowing people to exploit lower-ranked resources

Biogeografía Humana y Tendencia Demográfica en el Monte Nordpatagónico. Una aproximación arqueológica desde El Corcovo (SE de Mendoza)

The present paper attempt to improve the knowledge of human biogeography in arid environments and, understand the phases of settlement in relation to human demographic trajectories. In this framework, new archaeological information of the El Corcovo area is presented, located in Monte Surmendocino / Nordpatagónico. The field-works that contemplated transects, archaeological excavation of a site and the surveying of rock art of three others are detailed. The results indicate the beginning of occupations around 1900 years 14C AP and a change in the pattern of mobility around 600 years 14C AP. Both situations are consistent with the existing relative chronological estimates for the rock art of the area. Based on a regional demographic model for Monte area, the results show two pulses of increase in the human signal that correspond chronologically with the initial date of occupation estimated for the area and with the date obtained for the proposed change. By associating these pulses with significant falls in the phyto-geographic sector of Patagonia, alternative explanations on population dynamics are postulated.El presente trabajo aporta al conocimiento de la biogeografía humana en ambientes áridos y las fases de poblamiento en relación con las trayectorias demográficas humanas. En ese marco, se presenta nueva información arqueológica del área El Corcovo, emplazada en el Monte surmendocino/nordpatagónico. Se detallan los trabajos de campo que contemplaron transectas, excavación arqueológica de un sitio y el relevamiento de arte rupestre de otros tres. Los resultados señalan el inicio de las ocupaciones en torno a 1900 años 14C AP y un cambio en el patrón de movilidad en torno a 600 años 14C AP. Ambas situaciones son consistentes con las estimaciones cronológicas relativas existentes para el arte rupestre del área. Con base en un modelo demográfico regional del Monte, los resultados encuentran dos pulsos de incremento en la señal humana que se corresponden cronológicamente con la fecha inicial de ocupación estimada para el área y con la fecha obtenida para el cambio propuesto. Al asociarse estos pulsos con disminuciones significativas en el sector fitogeográfico de Patagonia se postulan explicaciones alternativas sobre la dinámica poblacional.

A first search for coincident gravitational waves and high energy neutrinos using LIGO, Virgo and ANTARES data from 2007

We present the results of the first search for gravitational wave bursts associated with high energy neutrinos. Together, these messengers could reveal new, hidden sources that are not observed by conventional photon astronomy, particularly at high energy. Our search uses neutrinos detected by the underwater neutrino telescope ANTARES in its 5 line configuration during the period January - September 2007, which coincided with the fifth and first science runs of LIGO and Virgo, respectively. The LIGO-Virgo data were analysed for candidate gravitational-wave signals coincident in time and direction with the neutrino events. No significant coincident events were observed. We place limits on the density of joint high energy neutrino - gravitational wave emission events in the local universe, and compare them with densities of merger and core-collapse events

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac